Published in Invest New Drugs on May 01, 2003
Development of a new pre- and post-processing tool (SADAPT-TRAN) for nonlinear mixed-effects modeling in S-ADAPT. AAPS J (2011) 1.71
Performance and robustness of the Monte Carlo importance sampling algorithm using parallelized S-ADAPT for basic and complex mechanistic models. AAPS J (2011) 1.26
Human neutrophil kinetics: modeling of stable isotope labeling data supports short blood neutrophil half-lives. Blood (2016) 0.94
Interpretation of transit compartments pharmacodynamic models as lifespan based indirect response models. J Pharmacokinet Pharmacodyn (2010) 0.93
Lifespan based indirect response models. J Pharmacokinet Pharmacodyn (2012) 0.81
A model qualification method for mechanistic physiological QSP models to support model-informed drug development. CPT Pharmacometrics Syst Pharmacol (2016) 0.79
Lifespan based pharmacokinetic-pharmacodynamic model of tumor growth inhibition by anticancer therapeutics. PLoS One (2014) 0.76
Understanding and applying pharmacometric modelling and simulation in clinical practice and research. Br J Clin Pharmacol (2016) 0.75
Clinical population pharmacokinetics and toxicodynamics of linezolid. Antimicrob Agents Chemother (2014) 0.75
Relationships between sirolimus dosing, concentration and outcomes in renal transplant recipients. Br J Clin Pharmacol (2005) 0.75
SEP enhanced the antitumor activity of 5-fluorouracil by up-regulating NKG2D/MICA and reversed immune suppression via inhibiting ROS and caspase-3 in mice. Oncotarget (2016) 0.75
Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med (1966) 7.30
Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med (1991) 6.33
Developmental potential and dynamic behavior of hematopoietic stem cells. Cell (1986) 5.98
Haemopoietic colony stimulating factors promote cell survival by suppressing apoptosis. Nature (1990) 3.80
Granulocyte colony-stimulating factor and its receptor. Blood (1991) 3.24
Leukokinetic studies. III. The distribution of granulocytes in the blood of normal subjects. J Clin Invest (1961) 2.84
THE KINETICS OF GRANULOPOIESIS IN NORMAL MAN. Blood (1964) 2.61
Pharmacokinetic/pharmacodynamic modeling in drug development. Annu Rev Pharmacol Toxicol (2000) 2.61
Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med (1998) 2.59
LEUKOKINETIC STUDIES. II. A METHOD FOR LABELING GRANULOCYTES IN VITRO WITH RADIOACTIVE DIISOPROPYLFLUOROPHOSPHATE (DFP). J Clin Invest (1960) 2.56
Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol (1998) 2.52
Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol (1995) 2.50
Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol (2002) 2.43
Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer (1987) 1.97
Cyclical neutropenia and other periodic hematological disorders: a review of mechanisms and mathematical models. Blood (1998) 1.79
Potential roles for preclinical pharmacology in phase I clinical trials. Cancer Treat Rep (1986) 1.79
Effect of recombinant granulocyte colony-stimulating factor on neutrophil kinetics in normal young and elderly humans. Blood (1996) 1.72
Neutrophil kinetics in man. J Clin Invest (1976) 1.72
Kinetic model of a bone-marrow stem-cell population. Br J Haematol (1962) 1.71
Most primitive hematopoietic stem cells are stimulated to cycle rapidly after treatment with 5-fluorouracil. Blood (1991) 1.58
Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N Engl J Med (1977) 1.54
The kinetics of human granulopoiesis following treatment with granulocyte colony-stimulating factor in vivo. Proc Natl Acad Sci U S A (1989) 1.38
Interferon-gamma and tumor necrosis factor-alpha suppress both early and late stages of hematopoiesis and induce programmed cell death. J Cell Physiol (1995) 1.33
Nature of the hemopoietic stem cell compartment and its proliferative potential. Blood Cells (1979) 1.26
Transit compartments versus gamma distribution function to model signal transduction processes in pharmacodynamics. J Pharm Sci (1998) 1.26
GRANULOCYTOPOIESIS. II. EMERGENCE AND PATTERN OF LABELING OF NEUTROPHILIC GRANULOCYTES IN HUMANS. Blood (1964) 1.21
Combining physiologic models and symbolic methods to interpret time-varying patient data. Methods Inf Med (1991) 1.19
Semiphysiological model for the time course of leukocytes after varying schedules of 5-fluorouracil in rats. J Pharmacol Exp Ther (2000) 1.17
Basic pharmacodynamic models for agents that alter production of natural cells. J Pharmacokinet Biopharm (1999) 1.17
Interleukin-6 induces demargination of intravascular neutrophils and shortens their transit in marrow. Am J Physiol Heart Circ Physiol (2000) 1.15
Blood transit and recirculation kinetics of lymphocyte subsets in normal rats. Scand J Immunol (1988) 1.08
Granulocyte transit from bone marrow to blood. Blood (1968) 1.02
Pharmacologically guided phase I clinical trials based upon preclinical drug development. J Natl Cancer Inst (1990) 1.02
Pharmacokinetics and pharmacodynamics of long-term continuous-infusion doxorubicin. Clin Pharmacol Ther (1989) 0.98
Pharmacokinetics of 5-fluorouracil assessed with a sensitive mass spectrometric method in patients on a dose escalation schedule. Cancer Res (1988) 0.95
Dose intensity for bolus versus infusion chemotherapy administration: review of the literature for 27 anti-neoplastic agents. Ann Oncol (1997) 0.95
Quantification of the cell kinetic effects of G-CSF using a model of human granulopoiesis. Exp Hematol (1993) 0.94
Experimental chemotherapy and concepts related to the cell cycle. Int J Radiat Biol Relat Stud Phys Chem Med (1986) 0.94
A general model for time-dissociated pharmacokinetic-pharmacodynamic relationship exemplified by paclitaxel myelosuppression. Clin Pharmacol Ther (1998) 0.93
Population pharmacokinetic-pharmacodynamic modeling of filgrastim (r-metHuG-CSF) in healthy volunteers. J Pharmacokinet Pharmacodyn (2001) 0.93
Circadian cancer therapy. J Clin Oncol (1993) 0.92
A randomized study of epirubicin at four different dose levels in advanced breast cancer. Feasibility of myelotoxicity prediction through single blood-sample measurement. Cancer Chemother Pharmacol (1991) 0.92
Computer simulation of granulopoiesis: normal and impaired granulopoiesis. Blood (1970) 0.91
Kinetics of the formed elements of human blood. Blood (1977) 0.90
Pharmacodynamic model of topotecan-induced time course of neutropenia. Clin Cancer Res (2001) 0.89
A mathematical model of canine granulocytopoiesis. J Math Biol (1980) 0.88
Adaptive control of etoposide administration: impact of interpatient pharmacodynamic variability. Clin Pharmacol Ther (1989) 0.88
Optimizing drug regimens in cancer chemotherapy by an efficacy-toxicity mathematical model. Comput Biomed Res (2000) 0.88
Population pharmacokinetics/toxicodynamics (PK/TD) relationship of SAM486A in phase I studies in patients with advanced cancers. J Clin Pharmacol (2000) 0.87
Cyclical neutropenia and the peripheral control of white blood cell production. J Theor Biol (1998) 0.87
Indirect-response model for the time course of leukopenia with anticancer drugs. Clin Pharmacol Ther (1998) 0.87
Optimizing drug regimens in cancer chemotherapy: a simulation study using a PK-PD model. Comput Biol Med (2001) 0.87
Models of schedule dependent haematological toxicity of 2'-deoxy-2'-methylidenecytidine (DMDC). Eur J Clin Pharmacol (2000) 0.86
Levels of recombinant human granulocyte colony-stimulating factor in serum are inversely correlated with circulating neutrophil counts. Antimicrob Agents Chemother (1996) 0.86
A population model for the leukopenic effect of etoposide. Clin Pharmacol Ther (1995) 0.83
Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole. J Clin Oncol (1991) 0.81
Pharmacodynamic modeling of the entire time course of leukopenia after a 3-hour infusion of paclitaxel. Jpn J Cancer Res (2001) 0.81
Mathematical model of granulocytopoiesis and chronic myelogenous leukemia. Cancer Res (1991) 0.81
Clinical and pharmacologic analysis of hyperfractionated daily oral etoposide. J Clin Oncol (1995) 0.80
Pharmacological analysis of etoposide in elderly patients with lung cancer. Clin Cancer Res (1999) 0.80
A simple model of a steady state differentiating cell system. J Cell Biol (1969) 0.80
The role of polymorphonuclear neutrophils (PMNs) in clearance of granulocyte colony-stimulating factor (G-CSF) in vivo and in vitro. Exp Hematol (1997) 0.79
Pharmacodynamic analysis of hematologic profiles. J Pharmacokinet Biopharm (1994) 0.79
The hematopoietic and mature blood cells of the rat: their morphology and the kinetics of circulating leukocytes in control rats. Exp Hematol (1991) 0.79
A concept of hemopoietic regulation and its biomathematical realization. Blood Cells (1988) 0.78
A mathematical model of the chemotherapeutic treatment of acute myeloblastic leukemia. Biophys J (1976) 0.78
Toxicity of cytostatic drugs to normal bone marrow cells in vitro. Cancer Chemother Pharmacol (1998) 0.78
Human pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic menogaril (7-OMEN, NSC 269148) and their correlation with clinical toxicities. Cancer Res (1986) 0.77
Modeling complex neutrophil dynamics in the grey collie. J Theor Biol (2000) 0.76
Pharmacodynamics of prolonged oral etoposide in patients with advanced non-small-cell lung cancer. J Clin Oncol (1993) 0.76
A mathematical model of neutrophil production and control in normal man. J Math Biol (2017) 0.75
Parameterization of in vivo leukemic cell populations. Biophys J (1971) 0.75
Therapeutic relevance of pharmacokinetics and pharmacodynamics. Semin Oncol (1992) 0.75
A comprehensive modeling procedure for the human granulopoietic system: over-all view and summary of data. Blood (1973) 0.75
Simulation of murine granulopoiesis. Blut (1980) 0.75
Assessment of myelotoxic effects of chemotherapy from early leukopenic response: application of a mathematical model for granulopoiesis. J Surg Oncol (1979) 0.75
Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J (2011) 4.60
Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J (2009) 3.99
Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn (2007) 3.00
Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharm Res (2007) 2.51
Likelihood based approaches to handling data below the quantification limit using NONMEM VI. J Pharmacokinet Pharmacodyn (2008) 2.50
Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis. J Clin Oncol (2002) 2.44
Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol (2002) 2.43
Handling data below the limit of quantification in mixed effect models. AAPS J (2009) 2.11
Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother (2004) 2.08
Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption. Antimicrob Agents Chemother (2008) 1.95
Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis. AAPS PharmSci (2002) 1.72
Approaches to handling pharmacodynamic baseline responses. J Pharmacokinet Pharmacodyn (2008) 1.59
Population pharmacokinetics of busulfan in children: increased evidence for body surface area and allometric body weight dosing of busulfan in children. Clin Cancer Res (2011) 1.57
CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors. J Natl Cancer Inst (2006) 1.48
Model-based approach to dose optimization of lopinavir/ritonavir when co-administered with rifampicin. Br J Clin Pharmacol (2012) 1.48
Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res (2003) 1.42
Population pharmacokinetic and pharmacodynamic modelling of artemisinin and mefloquine enantiomers in patients with falciparum malaria. Eur J Clin Pharmacol (2002) 1.38
Semimechanistic pharmacokinetic/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments. Antimicrob Agents Chemother (2006) 1.36
Impact of omission or replacement of data below the limit of quantification on parameter estimates in a two-compartment model. Pharm Res (2002) 1.30
A semiphysiological pharmacokinetic model for artemisinin in healthy subjects incorporating autoinduction of metabolism and saturable first-pass hepatic extraction. Br J Clin Pharmacol (2005) 1.28
PopED: an extended, parallelized, nonlinear mixed effects models optimal design tool. Comput Methods Programs Biomed (2012) 1.27
Estimating bias in population parameters for some models for repeated measures ordinal data using NONMEM and NLMIXED. J Pharmacokinet Pharmacodyn (2004) 1.24
Models for time-varying covariates in population pharmacokinetic-pharmacodynamic analysis. Br J Clin Pharmacol (2004) 1.22
Use of prior information to stabilize a population data analysis. J Pharmacokinet Pharmacodyn (2002) 1.19
Intravenously administered digoxin in patients with acute atrial fibrillation: a population pharmacokinetic/pharmacodynamic analysis based on the Digitalis in Acute Atrial Fibrillation trial. Eur J Clin Pharmacol (2003) 1.18
Assessment of type I error rates for the statistical sub-model in NONMEM. J Pharmacokinet Pharmacodyn (2002) 1.17
A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080. J Pharmacokinet Pharmacodyn (2010) 1.16
Rapid sample size calculations for a defined likelihood ratio test-based power in mixed-effects models. AAPS J (2012) 1.16
Semiparametric distributions with estimated shape parameters. Pharm Res (2009) 1.15
Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults. Antimicrob Agents Chemother (2012) 1.13
Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin Cancer Res (2005) 1.13
Performance in population models for count data, part I: maximum likelihood approximations. J Pharmacokinet Pharmacodyn (2009) 1.13
Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea. Clin Pharmacol Ther (2002) 1.08
Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs. Clin Cancer Res (2006) 1.06
A fast method for testing covariates in population PK/PD Models. AAPS J (2011) 1.05
Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability. Br J Clin Pharmacol (2003) 1.04
Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis. Antimicrob Agents Chemother (2013) 1.03
The use of clinical irrelevance criteria in covariate model building with application to dofetilide pharmacokinetic data. J Pharmacokinet Pharmacodyn (2008) 1.01
Modelling overdispersion and Markovian features in count data. J Pharmacokinet Pharmacodyn (2009) 1.01
Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam. Invest New Drugs (2005) 1.01
Pharmacokinetics of desmopressin administrated as an oral lyophilisate dosage form in children with primary nocturnal enuresis and healthy adults. J Clin Pharmacol (2006) 1.01
Performance comparison of various maximum likelihood nonlinear mixed-effects estimation methods for dose-response models. AAPS J (2012) 0.99
Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms. Pharmacogenet Genomics (2008) 0.99
An integrated glucose-insulin model to describe oral glucose tolerance test data in type 2 diabetics. J Clin Pharmacol (2007) 0.97
A time-to-event pharmacodynamic model describing treatment response in patients with pulmonary tuberculosis using days to positivity in automated liquid mycobacterial culture. Antimicrob Agents Chemother (2012) 0.97
Pharmacokinetic/pharmacodynamic models for the depletion of Vbeta5.2/5.3 T cells by the monoclonal antibody ATM-027 in patients with multiple sclerosis, as measured by FACS. Br J Clin Pharmacol (2004) 0.96
Shrinkage in nonlinear mixed-effects population models: quantification, influencing factors, and impact. AAPS J (2012) 0.96
An integrated model for glucose and insulin regulation in healthy volunteers and type 2 diabetic patients following intravenous glucose provocations. J Clin Pharmacol (2007) 0.96
Evaluation of the nonparametric estimation method in NONMEM VI. Eur J Pharm Sci (2008) 0.95
Application of population pharmacokinetics to cladribine. BMC Pharmacol (2005) 0.95
Multinomial logistic estimation of Markov-chain models for modeling sleep architecture in primary insomnia patients. J Pharmacokinet Pharmacodyn (2010) 0.95
Population pharmacokinetics of ethambutol in South African tuberculosis patients. Antimicrob Agents Chemother (2011) 0.95
Pharmacokinetics and renal excretion of desmopressin after intravenous administration to healthy subjects and renally impaired patients. Br J Clin Pharmacol (2004) 0.94
A Phase I study of CHS 828 in patients with solid tumor malignancy. Clin Cancer Res (2002) 0.94
Modelling a spontaneously reported side effect by use of a Markov mixed-effects model. J Pharmacokinet Pharmacodyn (2005) 0.94
Mechanistic modelling of tesaglitazar pharmacokinetic data in subjects with various degrees of renal function--evidence of interconversion. Br J Clin Pharmacol (2008) 0.93
A population pharmacokinetic analysis of sildenafil citrate in patients with erectile dysfunction. Br J Clin Pharmacol (2002) 0.93
An integrated glucose-insulin model to describe oral glucose tolerance test data in healthy volunteers. J Clin Pharmacol (2009) 0.92
Simultaneous optimal experimental design on dose and sample times. J Pharmacokinet Pharmacodyn (2009) 0.92
Pharmacokinetics of ximelagatran and relationship to clinical response in acute deep vein thrombosis. Clin Pharmacol Ther (2005) 0.92
Modeling of red blood cell life-spans in hematologically normal populations. J Pharmacokinet Pharmacodyn (2012) 0.92
Population pharmacokinetics of clomethiazole and its effect on the natural course of sedation in acute stroke patients. Br J Clin Pharmacol (2003) 0.90
Population pharmacokinetics of levosimendan in patients with congestive heart failure. Br J Clin Pharmacol (2003) 0.89
Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib. Clin Cancer Res (2007) 0.89
An integrated model for the glucose-insulin system. Basic Clin Pharmacol Toxicol (2009) 0.89
Comparison of proportional and differential odds models for mixed-effects analysis of categorical data. J Pharmacokinet Pharmacodyn (2008) 0.88
A semi-mechanistic model of the relationship between average glucose and HbA1c in healthy and diabetic subjects. J Pharmacokinet Pharmacodyn (2013) 0.88
Scaling the time-course of myelosuppression from rats to patients with a semi-physiological model. Invest New Drugs (2009) 0.88
A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy. Cancer Chemother Pharmacol (2005) 0.87
A model for glucose, insulin, and beta-cell dynamics in subjects with insulin resistance and patients with type 2 diabetes. J Clin Pharmacol (2010) 0.87
A time-to-event model for acute rejections in paediatric renal transplant recipients treated with ciclosporin A. Br J Clin Pharmacol (2013) 0.87
Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression. Cancer Chemother Pharmacol (2009) 0.86
Comparison of cytotoxicity of 2-chloro- 2'-arabino-fluoro-2'-deoxyadenosine (clofarabine) with cladribine in mononuclear cells from patients with acute myeloid and chronic lymphocytic leukemia. Haematologica (2003) 0.86
Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children. Antivir Ther (2012) 0.86
An integrated model for the effect of budesonide on ACTH and cortisol in healthy volunteers. Br J Clin Pharmacol (2007) 0.86
Modeling longitudinal daily seizure frequency data from pregabalin add-on treatment. J Clin Pharmacol (2011) 0.86
A positron emission tomography study in healthy volunteers to estimate mGluR5 receptor occupancy of AZD2066 - estimating occupancy in the absence of a reference region. Neuroimage (2013) 0.85
Assessment of glycemic response to an oral glucokinase activator in a proof of concept study: application of a semi-mechanistic, integrated glucose-insulin-glucagon model. J Pharmacokinet Pharmacodyn (2012) 0.85
Evaluation of bias, precision, robustness and runtime for estimation methods in NONMEM 7. J Pharmacokinet Pharmacodyn (2014) 0.85
Assessment of the relative in vivo potency of the hydroxylated metabolite of darifenacin in its ability to decrease salivary flow using pooled population pharmacokinetic-pharmacodynamic data. Br J Clin Pharmacol (2004) 0.85
Application of the optimal design approach to improve a pretransplant drug dose finding design for ciclosporin. J Clin Pharmacol (2011) 0.85
A population pharmacokinetic model for cefuroxime using cystatin C as a marker of renal function. Br J Clin Pharmacol (2006) 0.85
Transient lower esophageal sphincter relaxation pharmacokinetic-pharmacodynamic modeling: count model and repeated time-to-event model. J Pharmacol Exp Ther (2011) 0.85
Pharmacokinetic Interactions for Drugs with a Long Half-Life—Evidence for the Need of Model-Based Analysis. AAPS J (2016) 0.84
Optimal adaptive design in clinical drug development: a simulation example. J Clin Pharmacol (2007) 0.84
Model-based neutrophil-guided dose adaptation in chemotherapy: evaluation of predicted outcome with different types and amounts of information. Basic Clin Pharmacol Toxicol (2009) 0.84
The impact of misspecification of residual error or correlation structure on the type I error rate for covariate inclusion. J Pharmacokinet Pharmacodyn (2009) 0.84
Gastric acid secretion in the dog: a mechanism-based pharmacodynamic model for histamine stimulation and irreversible inhibition by omeprazole. J Pharmacokinet Pharmacodyn (2002) 0.84
A pharmacokinetic-pharmacodynamic model for duodenal levodopa infusion. Clin Neuropharmacol (2011) 0.84
A tool for neutrophil guided dose adaptation in chemotherapy. Comput Methods Programs Biomed (2008) 0.84
Improved utilization of ADAS-cog assessment data through item response theory based pharmacometric modeling. Pharm Res (2014) 0.84
Cytotoxic activity of a new paclitaxel formulation, Pacliex, in vitro and in vivo. Cancer Chemother Pharmacol (2004) 0.84
Performance of three estimation methods in repeated time-to-event modeling. AAPS J (2011) 0.84
A simultaneous analysis of the time-course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic myelosuppression model. Invest New Drugs (2010) 0.83
Two bootstrapping routines for obtaining imprecision estimates for nonparametric parameter distributions in nonlinear mixed effects models. J Pharmacokinet Pharmacodyn (2010) 0.83
Two-stage model-based clinical trial design to optimize phase I development of novel anticancer agents. Invest New Drugs (2009) 0.83
Serial correlation in optimal design for nonlinear mixed effects models. J Pharmacokinet Pharmacodyn (2012) 0.83
Modeling sleep data for a new drug in development using markov mixed-effects models. Pharm Res (2011) 0.83
Rescue therapy with high-dose oral phenobarbitone loading for refractory status epilepticus. J Paediatr Child Health (2009) 0.83